Clinical Tumor Anemia Registry (TAR)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1018 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-12-31

Study Completion Date

2016-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this registry is to record information of routine treatment of anemia in cancer patients in Germany. An overview of the current treatment of anemia in German outpatient centers and hospitals will be provided. Primary outcome parameters, e.g. improvement in hemoglobin levels and changes in QoL, as well as patient characteristics of different treatments will be analyzed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Anemia Cancer Hemoglobin Quality of Life FACT-An FACT-GP Erythropoiesis-Stimulating Agents (ESA) Epoetin Ferric Carboxymaltose Blood Transfusions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed malignant disease
* Hemoglobin level \< 11 g/dl (female) or \< 12 g/dl (male)
* Start of antianemic therapy no more than 7 days prior to informed consent
* Performance status 0 - 3 (Karnofsky-Index \>= 40%)
* Minimum age: 18 years
* Informed written consent

Exclusion Criteria

* Hypersensitivity against antianemic therapies
* Myelodysplastic Syndrome
* Experimental antianemic therapy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

iOMEDICO

Freiburg im Breisgau, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Steinmetz T, Schroder J, Plath M, Link H, Vogt M, Frank M, Marschner N. Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort Study-The Tumor Anemia Registry. Anemia. 2016;2016:8057650. doi: 10.1155/2016/8057650. Epub 2016 Feb 4.

Reference Type RESULT

PMID: 26966573 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

iOM TAR

Identifier Type: -

Identifier Source: org_study_id